SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

29 May 2024 Evaluate
The revenue for the March 2024 quarter is pegged at Rs. 15106.20 millions, about 7.78% up against Rs. 14016.30 millions recorded during the year-ago period.A slender decline of -23.65% was recorded to Rs. 647.60  millions from Rs. 848.20 millions in the corresponding previous quarter.Operating profit for the quarter ended March 2024 rose to 3074.40 millions as compared to 2091.10 millions of corresponding quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 15106.20 14016.30 7.78 61664.60 58146.20 6.05 61664.60 58146.20 6.05
Other Income 151.00 334.70 -54.88 1112.90 1111.90 0.09 1112.90 1111.90 0.09
PBIDT 3074.40 2091.10 47.02 13226.70 10230.40 29.29 13226.70 10230.40 29.29
Interest 240.60 176.90 36.01 1206.70 439.20 174.75 1206.70 439.20 174.75
PBDT 1890.60 1914.20 -1.23 10686.40 9791.20 9.14 10686.40 9791.20 9.14
Depreciation 617.60 592.10 4.31 2464.80 2286.30 7.81 2464.80 2286.30 7.81
PBT 1273.00 1322.10 -3.71 8221.60 7504.90 9.55 8221.60 7504.90 9.55
TAX 625.40 473.90 31.97 2917.50 2447.90 19.18 2917.50 2447.90 19.18
Deferred Tax 6.30 84.40 -92.54 37.40 208.40 -82.05 37.40 208.40 -82.05
PAT 647.60 848.20 -23.65 5304.10 5057.00 4.89 5304.10 5057.00 4.89
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 20.35 14.92 36.42 21.45 17.59 21.91 21.45 17.59 21.91

Ipca Laboratories Share Price

1536.40 5.80 (0.38%)
05-May-2026 13:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1815.30
Dr. Reddys Lab 1271.50
Cipla 1326.65
Zydus Lifesciences 910.55
Lupin 2345.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×